If clinical trials are successful, the new tenofovir microbicide gel that protects women against the HIV virus will be manufactured in South Africa.

By IPS Correspondents Reprint | | Print |

Jun 20 2011 (IPS) - Dr Henry Gabelnick, of CONRAD, says licensing makes it possible to produce the topical gel to fit in to several price structures. Tinus de Jager asked Gabelnick what rights the South Africans received.

[podcast]http://traffic.libsyn.com/ipsaudio/20110620_conrad_dejagert.mp3[/podcast]